Alpha 1-antitrypsin deficiency differential diagnosis: Difference between revisions
Mazia Fatima (talk | contribs) No edit summary |
Mazia Fatima (talk | contribs) No edit summary |
||
Line 234: | Line 234: | ||
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Viral serology | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Viral serology | ||
|- | |- | ||
! rowspan="6" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Jaundice | ! rowspan="6" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Jaundice]] | ||
! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Hepatocellular Jaundice | ! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Jaundice|Hepatocellular Jaundice]] | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Alcoholic hepatitis | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Alcoholic hepatitis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
Line 251: | Line 251: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Cirrhosis | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cirrhosis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
Line 263: | Line 263: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑/N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑/N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Thrombocytopenia]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Small liver on | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Liver|Small liver]] on [[ultrasound]] | ||
|- | |- | ||
!Alpha 1-antitrypsin deficiency | ![[Alpha 1-antitrypsin deficiency]] | ||
!+ | !+ | ||
!-/+ | !-/+ | ||
Line 278: | Line 278: | ||
!↑/N | !↑/N | ||
!- | !- | ||
!Serum alpha1-antitrypsin levels decreased | !Serum [[Alpha1-antitrypsin deficiency|alpha1-antitrypsin]] levels decreased | ||
!Hepatomegaly on CT | ![[Hepatomegaly]] on [[CT]] | ||
|- | |- | ||
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Cholestatic Jaundice | ! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cholestatic]] [[Jaundice]] | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Hepatitis A cholestatic type | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis]] A [[Cholestatic|cholestatic type]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
Line 294: | Line 294: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |HAV- AB | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[HAV infection|HAV- AB]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Abdominal ultrasound | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Ultrasound|Abdominal ultrasound]] | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |EBV / CMV hepatitis | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Epstein Barr virus|EBV]] / [[CMV|CMV hepatitis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
Line 309: | Line 309: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Positive serology | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |Positive [[serology]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |PCR or ELISA | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[PCR]] or [[Enzyme linked immunosorbent assay (ELISA)|ELISA]] | ||
|- | |- | ||
|} | |} | ||
Line 382: | Line 382: | ||
|[[Bacterial pneumonia]] | |[[Bacterial pneumonia]] | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|Productive | |[[Productive cough|Productive]] | ||
| + | | + | ||
| + | | + | ||
Line 400: | Line 400: | ||
** Ground glass appearance | ** Ground glass appearance | ||
|- | |- | ||
|Cystic Fibrosis | |[[Cystic Fibrosis]] | ||
| +/- | | +/- | ||
|Productive | |[[Productive cough|Productive]] | ||
| +/- | | +/- | ||
| - | | - | ||
| - | | - | ||
| + | | + | ||
|Cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction evidenced by : | |[[Cystic fibrosis]] transmembrane conductance regulator (CFTR) dysfunction evidenced by : | ||
* Elevated sweat chloride ≥60 mmol/L (on two occasions) | * Elevated [[Sweat chloride test|sweat chloride]] ≥60 mmol/L (on two occasions) | ||
* Presence of two disease-causing mutations in CFTR, one from each parental allele | * Presence of two disease-causing [[mutations]] in CFTR, one from each [[Allele|parental allele]] | ||
* Abnormal nasal potential difference | * Abnormal [[Potential difference|nasal potential difference]] | ||
| | |[[X-ray]] : | ||
Hyperinflation presents as: | Hyperinflation presents as: | ||
* | * Flattening of the [[diaphragm]] | ||
* | * Anterior bowing of the infant [[sternum]] | ||
* | * Increased retrosternal air space | ||
* | * Generalized [[pulmonary]] overinflation. | ||
* Multiple nodular densities represent mucus plugging and may present in finger-in-glove shape or as a combination of V- or Y-shaped branching and bandlike shadows. | * Multiple nodular densities represent [[Mucus|mucus plugging]] and may present in finger-in-glove shape or as a combination of V- or Y-shaped branching and bandlike shadows. | ||
Abdominal findings include dilated multiple loops of the small bowel are seen in neonatal meconium ileus | Abdominal findings include dilated multiple loops of the [[small bowel]] are seen in [[Meconium ileus|neonatal meconium ileus]]. | ||
|- | |- | ||
|Emphysema | |[[Emphysema]] | ||
| +/- | | +/- | ||
|Productive | |[[Productive cough|Productive]] | ||
| - | | - | ||
| + | | + | ||
Line 433: | Line 433: | ||
| + | | + | ||
| | | | ||
* Arterial blood gas analysis: mild-to-moderate hypoxemia without hypercapnia that progresses to worsening hypoxemia and hypercapnia develops. | * [[Arterial blood gases|Arterial blood gas analysis]]: mild-to-moderate [[hypoxemia]] without [[hypercapnia]] that progresses to worsening [[hypoxemia]] and [[hypercapnia]] develops. | ||
* Chronic hypoxemia may lead to polycythemia. | * Chronic [[hypoxemia]] may lead to [[polycythemia]]. | ||
* Sputum is mucoid and the predominant cells are macrophages. | * [[Sputum]] is mucoid and the predominant cells are [[macrophages]]. | ||
|Chest X-ray reveals signs of emphysema include: | |[[Chest X-rays|Chest X-ray]] reveals signs of [[emphysema]] include: | ||
* | * Flattening of [[diaphragm]] | ||
* | * Increased retrosternal air space (see on lateral chest films) | ||
* | * A long narrow [[heart]] shadow. | ||
* | * Tapering vascular shadows | ||
* | * Hyperlucency of the [[lungs]] | ||
|- | |- | ||
|Primary Ciliary Dyskinesia (Kartagener Syndrome) | |[[Primary ciliary dyskinesia|Primary Ciliary Dyskinesia]] ([[Kartagener's Syndrome|Kartagener Syndrome]]) | ||
| +/- | | +/- | ||
|Productive | |[[Productive cough|Productive]] | ||
| - | | - | ||
| + | | + | ||
| + | | + | ||
| + | | + | ||
|Low or absent amount of nasal nitric oxide (nNO) | |Low or absent amount of nasal [[nitric oxide]] (nNO) | ||
[[Mucociliary clearance]] may be useful for [[screening]], | |||
Confirmation with tests of ciliary function. | |||
|Chest X-ray reveals : | |[[Chest X-rays|Chest X-ray]] reveals : | ||
Bronchial wall thickening | [[Bronchial]] wall thickening | ||
Bronchiectasis and hyperinflation | [[Bronchiectasis]] and hyperinflation | ||
Cystic bronchiectasis with air-fluid levels may be visible | Cystic [[bronchiectasis]] with air-fluid levels may be visible | ||
Usually involves the lower and middle lobes. | Usually involves the lower and middle lobes. | ||
|- | |- | ||
|Alpha 1-antitrypsin deficiency | |[[Alpha 1-antitrypsin deficiency]] | ||
| +/- | | +/- | ||
|Productive | |[[Productive cough|Productive]] | ||
| - | | - | ||
| + | | + | ||
| + | | + | ||
| + | | + | ||
|Reduced concentration of serum alpha1-antitrypsin levels is diagnostic of AATD. | |Reduced concentration of serum [[Alpha1 antitrypsin|alpha1-antitrypsin levels]] is diagnostic of AATD. | ||
Moderate-to-severe airflow obstruction with an FEV1 | Moderate-to-severe airflow obstruction with an [[FEV1]] | ||
Reduced vital capacity | Reduced [[vital capacity]] | ||
Increased lung volumes secondary to air trapping (residual volume >120% of predicted value) are usually present | Increased [[lung volumes]] secondary to air trapping ([[residual volume]] >120% of predicted value) are usually present | ||
|Chest | |[[Chest X-rays|Chest X-ray]] Alpha1-antitrypsin deficiency (AATD) [[emphysema]] presents as: | ||
* a hyperlucent appearance because healthy tissue has been destroyed. | * a hyperlucent appearance because healthy tissue has been destroyed. | ||
* Affected regions also are described as oligemic because they lack the normal rich pattern of branching blood vessels. | * Affected regions also are described as oligemic because they lack the normal rich pattern of branching blood vessels. | ||
* An unusual characteristic in alpha1-antitrypsin deficiency is found in about | * An unusual characteristic in alpha1-antitrypsin deficiency is found in about 60% of PiZZ patients is a striking basilar distribution. | ||
* In contrast, cigarette smoking is associated with more severe apical disease. | * In contrast, [[cigarette smoking]] is associated with more severe apical disease. | ||
|} | |} | ||
AATD can present as neonatal jaundice. The | AATD can present as [[neonatal jaundice]]. The differential diagnosis for [[neonatal jaundice]] is: <ref name="pmid28145671">{{cite journal |vauthors=Fargo MV, Grogan SP, Saguil A |title=Evaluation of Jaundice in Adults |journal=Am Fam Physician |volume=95 |issue=3 |pages=164–168 |year=2017 |pmid=28145671 |doi= |url=}}</ref> | ||
{| align="center" | {| align="center" | ||
Line 494: | Line 495: | ||
| | | | ||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | {| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | ||
! rowspan="3 | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Etiology Of Neonatal Jaundice | ||
! colspan="4" rowspan="2 | ! colspan="4" rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |History and clinical manifestations | ||
! colspan="8 | ! colspan="8" style="background:#4479BA; color: #FFFFFF;" align="center" |Diagnosis | ||
|- | |- | ||
! colspan="6 | ! colspan="6" style="background:#4479BA; color: #FFFFFF;" align="center" |Lab Findings | ||
! rowspan="2 | ! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Other blood tests | ||
! rowspan="2 | ! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Other diagnostic | ||
|- | |- | ||
! rowspan="1 | ! rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Family history | ||
! | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Fever | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |RUQ Pain | |||
! | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Pruritis | ||
! colspan="1" rowspan="1 | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |AST | ||
! colspan="1" rowspan="1 | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |ALT | ||
! colspan="1" rowspan="1 | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |ALK | ||
! colspan="1" rowspan="1 | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |BLR Indirect | ||
! colspan="1" rowspan="1 | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |BLR Direct | ||
! colspan="1" rowspan="1 | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" |Viral serology | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Alpha-1 antitrypsin deficiency | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Alpha 1-antitrypsin deficiency|Alpha-1 antitrypsin deficiency]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
Line 524: | Line 525: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Genetic testing | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Genetic testing]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Liver biopsy | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Liver biopsy]] | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Breast feeding failure jaundice | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Breast feeding]] failure [[jaundice]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki> | ||
Line 541: | Line 542: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki> | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Breast Milk Jaundice | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Breast-feeding|Breast Milk]] [[Jaundice]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki> | ||
Line 555: | Line 556: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>-</nowiki> | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Crigler-Najjar type 2 | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Crigler-Najjar Syndrome|Crigler-Najjar type 2]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
Line 566: | Line 567: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| colspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Genetic testing | | colspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Genetic testing]] | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Gilbert Syndrome | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Gilbert's Syndrome|Gilbert Syndrome]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
Line 579: | Line 580: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| colspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Genetic testing | | colspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Genetic testing]] | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Rotor syndrome | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Rotor syndrome]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
Line 592: | Line 593: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Genetic testing | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Genetic testing]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Liver biopsy | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Liver biopsy]] | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Dubin-Johnson syndrome | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Dubin-Johnson syndrome]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
Line 606: | Line 607: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Genetic testing | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Genetic testing]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Liver biopsy | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Liver biopsy]] | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Hereditory spherocytosis | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hereditary spherocytosis|Hereditory spherocytosis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
Line 620: | Line 621: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Genetic testing | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Genetic testing]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Osmotic fragility | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Osmotic|Osmotic fragility]] | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |G6PD deficiency | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[G6PD deficiency]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
Line 634: | Line 635: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| colspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Genetic testing | | colspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Genetic testing]] | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Thalassemia | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Thalassemia]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
Line 647: | Line 648: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| colspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Genetic testing | | colspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Genetic testing]] | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Sickle cell disease | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Sickle cell disease]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
Line 660: | Line 661: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| colspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Genetic testing | | colspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Genetic testing]] | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Immune hemolysis | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Immune]] [[hemolysis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
Line 673: | Line 674: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| colspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Autoantibodies | | colspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Autoantibodies]] | ||
|- | |- | ||
|} | |} |
Revision as of 21:41, 5 January 2018
Alpha 1-antitrypsin deficiency Microchapters |
Differentiating Alpha 1-antitrypsin deficiency from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Alpha 1-antitrypsin deficiency differential diagnosis On the Web |
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency differential diagnosis |
FDA on Alpha 1-antitrypsin deficiency differential diagnosis |
CDC on Alpha 1-antitrypsin deficiency differential diagnosis |
Alpha 1-antitrypsin deficiency differential diagnosis in the news |
Blogs on Alpha 1-antitrypsin deficiency differential diagnosis |
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency |
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]
Overview
Alpha 1-antitrypsin deficiency has to be differentiated from other conditions with similar presentation like autoimmune hepatitis, bronchiectasis, bronchitis, chronic obstructive pulmonary disease (COPD),cystic fibrosis,emphysema,primary ciliary dyskinesia (Kartagener Syndrome),viral hepatitis.
Differentiating Alpha 1-antitrypsin deficiency from Other Diseases
Alpha 1-antitrypsin deficiency presents with symptoms of emphysema associated with compromised liver function tests and/or cirrhosis. Differential diagnosis of includes:
Jaundice and RUQ pain differential diagnosis are:
|
The differential diagnosis of jaundice, fever, and RUQ pain are:
|
Diseases | Symptoms | Signs | Diagosis | |||||
---|---|---|---|---|---|---|---|---|
Fever | Cough | Chest pain | Wheezes | Crackles | Tachypnea | Lab tests | Imaging | |
Asthma | - | Dry/Productive | - | + | - | + |
|
|
Bronchiolitis | +/- | Dry | - | + | + | +/- |
|
|
COPD | + | Productive | - | + | + | + |
|
|
Bacterial pneumonia | + | Productive | + | + | + | +/- |
|
|
Cystic Fibrosis | +/- | Productive | +/- | - | - | + | Cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction evidenced by :
|
X-ray :
Hyperinflation presents as:
Abdominal findings include dilated multiple loops of the small bowel are seen in neonatal meconium ileus. |
Emphysema | +/- | Productive | - | + | +/- | + |
|
Chest X-ray reveals signs of emphysema include:
|
Primary Ciliary Dyskinesia (Kartagener Syndrome) | +/- | Productive | - | + | + | + | Low or absent amount of nasal nitric oxide (nNO)
Mucociliary clearance may be useful for screening, Confirmation with tests of ciliary function. |
Chest X-ray reveals :
Bronchial wall thickening Bronchiectasis and hyperinflation Cystic bronchiectasis with air-fluid levels may be visible Usually involves the lower and middle lobes. |
Alpha 1-antitrypsin deficiency | +/- | Productive | - | + | + | + | Reduced concentration of serum alpha1-antitrypsin levels is diagnostic of AATD.
Moderate-to-severe airflow obstruction with an FEV1 Reduced vital capacity Increased lung volumes secondary to air trapping (residual volume >120% of predicted value) are usually present |
Chest X-ray Alpha1-antitrypsin deficiency (AATD) emphysema presents as:
|
AATD can present as neonatal jaundice. The differential diagnosis for neonatal jaundice is: [3]
|
References
- ↑ Ghanei M, Tazelaar HD, Chilosi M, Harandi AA, Peyman M, Akbari HM; et al. (2008). "An international collaborative pathologic study of surgical lung biopsies from mustard gas-exposed patients". Respir Med. 102 (6): 825–30. doi:10.1016/j.rmed.2008.01.016. PMID 18339530.
- ↑ Lazović B, Svenda MZ, Mazić S, Stajić Z, Delić M (2013). "Analysis of electrocardiogram in chronic obstructive pulmonary disease patients". Med Pregl. 66 (3–4): 126–9. PMID 23653989.
- ↑ Fargo MV, Grogan SP, Saguil A (2017). "Evaluation of Jaundice in Adults". Am Fam Physician. 95 (3): 164–168. PMID 28145671.